FDA approves fremanezumab-vfrm as a preventive treatment for migraines in adults

migraine is a common chronic neurovascular disease, characterized by recurrent seizures, one-sided or double-sided throbbing severe headache and mostly occurs in the side of the head, can be combined with autoimmune nervous system dysfunction such as nausea, vomiting, fear of light and fear of sound and other symptoms, about 1/3 of migraine patients before the onset of the disease can appear the symptoms of the nervous system precursorrecently, Teva Pharmaceutical Industries announced that itfdato approve its Ajovy (fremanezumab-vfrm) as a preventive treatment for migraines in adultsAjovy
Ajovy is a humanized CGRP monoclonal antibody that was granted priority review of migraine indications by the FDA in December and a rapid-track qualification for cluster headache indicationsCGRP has been proven to be a key target in migraines, and Ajovy acts as a preventive preventer by combining with CGRP to block CGRP from binding to its receptorsAjovy has 225 mg and 675 mg doses, which require a monthly or every three months to prevent migraine attacksthe study
this approval is based on two clinical 3trials with placeboin which patients with deactivation migraine sittative migraines were treated as a single therapy or a combination of Ajovy and other oral prophylaxisThe results showed a significant reduction in the number of days of migraines per month during the 12-week trial